Dexcom’s Game-Changing Strategy: Is the Type 2 Diabetes Market Its Next Goldmine?

DexCom Inc.’s latest financial performance for the third quarter of 2025 revealed a mixture of strengths and challenges, reflected in both strategic updates and financial metrics. The company reported a 22% increase in worldwide revenue, reaching $1.21 billion compared to $994 million in the same quarter last year. This growth was driven by strong performance in both the U.S. and international markets, particularly due to expanded continuous glucose monitoring (CGM) access and the broadening of their customer base across the type 2 diabetes population. In the U.S., the company noted a significant rise in new customer starts from the type 2 diabetes cohort, particularly among non-insulin users. With coverage now established for nearly 6 million type 2 non-insulin lives, representing about half of the commercial population in the U.S., DexCom continues to focus on achieving broader coverage for the remaining type 2 population.